Similar articles

• Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.

  Fantoni M, Del Borgo C, Autore C, Barbaro G. Fantoni M, et al. Ital Heart J. 2002 May;3(5):294-9. Ital Heart J. 2002. PMID: 12066561 Review.
• Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.

  Barbaro G. Barbaro G. Curr HIV Res. 2006 Jan;4(1):79-85. doi: 10.2174/157016206775197664. Curr HIV Res. 2006. PMID: 16454713 Review.
• [Metabolic disturbances associated with HAART].

  Olczak A. Olczak A. Przegl Epidemiol. 2007;61(4):639-46. Przegl Epidemiol. 2007. PMID: 18572495 Review. Polish.
• HIV protease inhibitors and obesity.

  Anuurad E, Bremer A, Berglund L. Anuurad E, et al. Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):478-85. doi: 10.1097/MED.0b013e32833dde87. Curr Opin Endocrinol Diabetes Obes. 2010. PMID: 20717021 Free PMC article. Review.
• Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?

  Bradbury RA, Samaras K. Bradbury RA, et al. Diabetes Obes Metab. 2008 Jun;10(6):441-50. doi: 10.1111/j.1463-1326.2007.00760.x. Epub 2007 Sep 6. Diabetes Obes Metab. 2008. PMID: 17825081 Review.